Is Analysis of Inflammatory Biomarkers and Lymphocyte Subpopulations Useful in Prediction of Tuberculosis Treatment Outcomes?

Overview

Journal J Clin Tuberc Other Mycobact Dis

Date 2021 Sep 20

PMID 34541339

Authors

Greta Musteikiene

Skaidrius Miliauskas

Jurgita Zaveckiene

Daiva Urboniene

Astra Vitkauskiene

Marius Zemaitis

Albinas Naudziunas

Affiliations

Soon will be listed here.

Abstract

Analysis of inflammatory biomarkers and lymphocytes during the treatment of tuberculosis (TB) could yield findings that influence the routine clinical practice and use of new anti-TB drugs. This study aimed to evaluate whether the selected biomarkers-soluble intercellular adhesion molecule type 1, soluble urokinase-type plasminogen activator receptor (suPAR), and C-reactive protein (CRP)-and T-cell subpopulations are useful for predicting culture conversion, treatment outcomes, and the extent of radiological lesions (calculated using X-ray score) in patients with drug-sensitive pulmonary TB. This study included 62 patients with drug-sensitive pulmonary TB. CRP and suPAR levels significantly decreased after 1 month of treatment. Before treatment initiation, CRP and suPAR levels were significantly higher in patients without culture conversion; however, none of the selected host biomarkers appeared to significantly influence the conversion status or treatment outcomes. Some lymphocyte subpopulations were correlated with X-ray scores before TB treatment initiation, but lung destruction, as determined using X-ray scores, showed the highest correlation with the baseline CRP value. We conclude that selected host biomarkers have a very limited role in predicting TB treatment outcomes and culture conversion and do not appear to be superior to CRP in monitoring TB treatment.

Citing Articles

Identification of Factors Determining Patterns of Serum C-Reactive Protein Level Reduction in Response to Treatment Initiation in Patients with Drug-Susceptible Pulmonary Tuberculosis.

Kivrane A, Ulanova V, Grinberga S, Sevostjanovs E, Viksna A, Ozere I Antibiotics (Basel). 2025; 13(12.

PMID: 39766606 PMC: 11672611. DOI: 10.3390/antibiotics13121216.

References

Godtfredsen N, Jorgensen D, Marsaa K, Ulrik C, Andersen O, Eugen-Olsen J . Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD. Respir Res. 2018; 19(1):97. PMC: 5963104. DOI: 10.1186/s12931-018-0803-2. View

Ni W, Han Y, Zhao J, Cui J, Wang K, Wang R . Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis. Sci Rep. 2016; 6:39481. PMC: 5172370. DOI: 10.1038/srep39481. View

Agrawal S, Parkash O, Palaniappan A, Bhatia A, Kumar S, Chauhan D . Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response. Front Immunol. 2018; 9:157. PMC: 5810270. DOI: 10.3389/fimmu.2018.00157. View

Acharya M, Pradeep S, Murthy V, Chikkannaiah P, Kambar V, Narayanashetty S . CD38+CD27-TNF-α + on Mtb-specific CD4+ T Cells Is a Robust Biomarker for Tuberculosis Diagnosis. Clin Infect Dis. 2021; 73(5):793-801. DOI: 10.1093/cid/ciab144. View

Rodrigues D, Medeiros E, Weckx L, Bonnez W, Salomao R, Kallas E . Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease. Clin Exp Immunol. 2002; 128(1):149-54. PMC: 1906372. DOI: 10.1046/j.1365-2249.2002.01809.x. View

Harding C, Boom W . Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat Rev Microbiol. 2010; 8(4):296-307. PMC: 3037727. DOI: 10.1038/nrmicro2321. View

Goovaerts O, Jennes W, Massinga-Loembe M, Ondoa P, Ceulemans A, Vereecken C . Lower Pre-Treatment T Cell Activation in Early- and Late-Onset Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. PLoS One. 2015; 10(7):e0133924. PMC: 4514632. DOI: 10.1371/journal.pone.0133924. View

Plit M, Theron A, Fickl H, Van Rensburg C, Pendel S, Anderson R . Influence of antimicrobial chemotherapy and smoking status on the plasma concentrations of vitamin C, vitamin E, beta-carotene, acute phase reactants, iron and lipid peroxides in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 1998; 2(7):590-6. View

Djoba Siawaya J, Bapela N, Ronacher K, Veenstra H, Kidd M, Gie R . Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. J Infect. 2008; 56(5):340-7. DOI: 10.1016/j.jinf.2008.02.007. View

10.

Qian Q, Zhan P, Sun W, Zhang Y, Song Y, Yu L . Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control. Neoplasma. 2012; 59(4):433-9. DOI: 10.4149/neo_2012_056. View

11.

Scott G, Murphy P, Gemidjioglu M . Predicting deterioration of treated tuberculosis by corticosteroid reserve and C-reactive protein. J Infect. 1990; 21(1):61-9. DOI: 10.1016/0163-4453(90)90669-y. View

12.

Zeng M, Chang M, Zheng H, Li B, Chen Y, He W . Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis. Am J Emerg Med. 2015; 34(3):375-80. DOI: 10.1016/j.ajem.2015.11.004. View

13.

BECK J, Potts R, Kardjito T, Grange J . T4 lymphopenia in patients with active pulmonary tuberculosis. Clin Exp Immunol. 1985; 60(1):49-54. PMC: 1577009. View

14.

Ralph A, Ardian M, Wiguna A, Maguire G, Becker N, Drogumuller G . A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax. 2010; 65(10):863-9. DOI: 10.1136/thx.2010.136242. View

15.

Bernal-Fernandez G, Hermida C, Espinosa-Cueto P, Cubilla-Tejeda A, Salazar-Gonzalez J, Ortiz-Ortiz L . Impact of opportunistic Mycobacterium tuberculosis infection on the phenotype of peripheral blood T cells of AIDS patients. J Clin Lab Anal. 2006; 20(3):80-6. PMC: 6807506. DOI: 10.1002/jcla.20105. View

16.

Latorre I, Fernandez-Sanmartin M, Muriel-Moreno B, Villar-Hernandez R, Vila S, De Souza-Galvao M . Study of CD27 and CCR4 Markers on Specific CD4 T-Cells as Immune Tools for Active and Latent Tuberculosis Management. Front Immunol. 2019; 9:3094. PMC: 6334476. DOI: 10.3389/fimmu.2018.03094. View

17.

Musteikiene G, Miliauskas S, Zaveckiene J, Zemaitis M, Vitkauskiene A . Factors associated with sputum culture conversion in patients with pulmonary tuberculosis. Medicina (Kaunas). 2018; 53(6):386-393. DOI: 10.1016/j.medici.2018.01.005. View

18.

Demir T, Yalcinoz C, Keskinel I, Demiroz F, Yildirim N . sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2002; 6(2):155-9. View

19.

Walzl G, Ronacher K, Djoba Siawaya J, Dockrell H . Biomarkers for TB treatment response: challenges and future strategies. J Infect. 2008; 57(2):103-9. DOI: 10.1016/j.jinf.2008.06.007. View

20.

Eugen-Olsen J, Gustafson P, Sidenius N, Fischer T, Parner J, Aaby P . The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis. 2002; 6(8):686-92. View